Fig. 1

Distribution of minimum inhibitory concentration for imipenem/cilastatin/relebactam (a), ceftazidime/avibactam (b) and meropenem/vaborbactam (c) within the 603 KPC-producing Klebsiella pneumoniae strains analysed in the study